Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 2/20 | 0.46 |
| ▸ | FAAH | O00519 | 2/20 | 0.44 |
| ▸ | UBE2M | P61081 | 7/20 | 0.42 |
| ▸ | DCUN1D1 | Q96GG9 | 7/20 | 0.42 |
| ▸ | ACKR3 | P25106 | 3/20 | 0.41 |
| ▸ | CNR2 | P34972 | 2/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.40 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16249963 | 0.96 | CHRM3 (0.45) | CHRM3FAAHUBE2MDCUN1D1ACKR3 | |
| Trifluoroacetic Acid SCHEMBL16238254 | 0.93 | FAAH (0.43) | CHRM3FAAHUBE2MDCUN1D1ACKR3 | |
| SCHEMBL17618795 | 0.87 | CNR2 (0.49) | FAAHUBE2MDCUN1D1ACKR3CNR2 | |
| SCHEMBL19699081 | 0.85 | IDH2 (0.46) | FAAHMEN1MAPTKMT2A | |
| SCHEMBL17618875 | 0.83 | KMT2A (0.41) | FAAHUBE2MDCUN1D1MEN1MAPT | |
| SCHEMBL17618783 | 0.83 | MEN1 (0.47) | MEN1MAPTKMT2A | |
| SCHEMBL16249974 | 0.81 | HTR2C (0.49) | FAAHMEN1KMT2A | |
| SCHEMBL19706095 | 0.81 | CHRM3 (0.41) | CHRM3CNR2TRPV4HTR6CNR1 | |
| SCHEMBL17618348 | 0.80 | IDH2 (0.45) | FAAHMEN1MAPTKMT2A | |
| SCHEMBL16238014 | 0.80 | MEN1 (0.38) | MEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180044338-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2018-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180044338-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | CHRM3 4560/4885FAAH 1092/4885UBE2M 379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.